Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AHAC Alpha Healthcare Acquisition	$10.96	$10.41	$9.12 ▼ $16.96	$140.89M	N/A	341,126 shs	298,128 shs
CGEM Cullinan Therapeutics	$7.53 -3.1%	$8.02	$6.85 ▼ $21.01	$444.35M	-0.08	497,243 shs	221,414 shs
DNA Ginkgo Bioworks	$10.13 +3.8%	$8.94	$5.00 ▼ $16.85	$592.91M	1.48	1.43 million shs	1.55 million shs
MGTX MeiraGTx	$8.62	$6.45	$3.85 ▼ $8.98	$692.70M	1.24	408,860 shs	400,903 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AHAC Alpha Healthcare Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
CGEM Cullinan Therapeutics	0.00%	-2.21%	-1.83%	-7.04%	-58.83%
DNA Ginkgo Bioworks	0.00%	+1.50%	+18.72%	+37.82%	-24.24%
MGTX MeiraGTx	0.00%	+1.77%	+35.96%	+52.57%	+95.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AHAC Alpha Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	1.9429 of 5 stars	3.5	0.0	0.0	0.0	2.7	1.7	0.6
DNA Ginkgo Bioworks	0.8848 of 5 stars	1.0	1.0	0.0	0.0	2.5	2.5	1.3
MGTX MeiraGTx	3.9151 of 5 stars	3.5	1.0	0.0	4.8	1.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AHAC Alpha Healthcare Acquisition	0.00	N/A	N/A	N/A
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	298.41% Upside
DNA Ginkgo Bioworks	2.00	Hold	$8.50	-16.09% Downside
MGTX MeiraGTx	3.00	Buy	$24.00	178.42% Upside

Current Analyst Ratings Breakdown

Latest AHAC, DNA, MGTX, and CGEM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AHAC Alpha Healthcare Acquisition	N/A	N/A	$0.12 per share	92.25	$0.39 per share	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
DNA Ginkgo Bioworks	$227.04M	2.61	N/A	N/A	$13.17 per share	0.77
MGTX MeiraGTx	$33.28M	20.81	N/A	N/A	$0.87 per share	9.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AHAC Alpha Healthcare Acquisition	$1.42M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	-$167.38M	-$2.91	N/A	N/A	N/A	N/A	-29.47%	-28.19%	8/6/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$9.16	N/A	N/A	N/A	-198.84%	-52.35%	-27.14%	8/14/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	22.68	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)

Latest AHAC, DNA, MGTX, and CGEM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.7951	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	MGTX MeiraGTx	-$0.52	N/A	N/A	N/A	$8.00 million	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AHAC Alpha Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AHAC Alpha Healthcare Acquisition	N/A	2.10	2.10
CGEM Cullinan Therapeutics	N/A	11.62	11.62
DNA Ginkgo Bioworks	N/A	4.88	4.88
MGTX MeiraGTx	2.34	1.53	1.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AHAC Alpha Healthcare Acquisition	19.00%
CGEM Cullinan Therapeutics	86.31%
DNA Ginkgo Bioworks	78.63%
MGTX MeiraGTx	67.48%

Insider Ownership

Company	Insider Ownership
AHAC Alpha Healthcare Acquisition	N/A
CGEM Cullinan Therapeutics	6.07%
DNA Ginkgo Bioworks	9.72%
MGTX MeiraGTx	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AHAC Alpha Healthcare Acquisition	N/A	12.86 million	N/A	Not Optionable
CGEM Cullinan Therapeutics	30	59.01 million	55.43 million	Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable

AHAC, DNA, MGTX, and CGEM Headlines

Recent News About These Companies

MeiraGTx (NASDAQ:MGTX) Hits New 12-Month High - Here's What Happened

July 16, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Shares Gap Down - What's Next?

July 11, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Sets New 1-Year High - Here's Why

July 10, 2025 | marketbeat.com

MeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past week

July 9, 2025 | finance.yahoo.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) CEO Alexandria Forbes Sells 47,500 Shares

July 8, 2025 | marketbeat.com

Insider Sell Alert: Alexandria Forbes Sells 47,500 Shares of MeiraGTx Holdings PLC

July 8, 2025 | gurufocus.com

MeiraGTx (NASDAQ:MGTX) Rating Increased to Hold at Wall Street Zen

July 5, 2025 | marketbeat.com

MeiraGTx Holdings PLC News (MGTX) - Investing.com

July 3, 2025 | investing.com

MeiraGTx Holdings plc (MGTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

MeiraGTx (NASDAQ:MGTX) Stock Price Up 7.8% - Here's Why

July 2, 2025 | marketbeat.com

42,115 Shares in MeiraGTx Holdings PLC (NASDAQ:MGTX) Purchased by Acuitas Investments LLC

July 2, 2025 | marketbeat.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) Shares Acquired by Janney Montgomery Scott LLC

July 1, 2025 | marketbeat.com

3 Promising Genomics Stocks to Keep an Eye On in 2025

June 27, 2025 | zacks.com

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025 | globenewswire.com

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025 | globenewswire.com

FDA grants RMAT status to MeiraGTx’s Parkinson’s treatment

May 10, 2025 | investing.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 9, 2025 | finance.yahoo.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

May 9, 2025 | globenewswire.com

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

April 29, 2025 | globenewswire.com

Richard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) Stock

April 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AHAC, DNA, MGTX, and CGEM Company Descriptions

Alpha Healthcare Acquisition NASDAQ:AHAC

Alpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Cullinan Therapeutics NASDAQ:CGEM

$7.53 -0.24 (-3.09%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.52 0.00 (-0.07%)

As of 07/18/2025 04:20 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Ginkgo Bioworks NYSE:DNA

$10.13 +0.37 (+3.79%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$10.24 +0.11 (+1.14%)

As of 07/18/2025 07:59 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

MeiraGTx NASDAQ:MGTX

$8.62 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.62 0.00 (0.00%)

As of 07/18/2025 04:33 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time